Redaktion

Ich kann leider das spezifische JLE-Artikel nicht in den verfügbaren Suchergebnissen finden. Die Suchergebnisse enthalten andere hochwertige Quellen zu generalisierten pustulösen Psoriasis (GPP), aber nicht den exakten Artikel von JLE mit dem Fokus auf Mortalität, Prävalenz, Komorbiditäten und Schübe. Um den Artikel für Sie zusammenzufassen, benötige ich entweder: - Den vollständigen Text oder die Zusammenfassung des JLE-Artikels - Oder Zugriff auf die spezifische URL mit dem Artikel-Inhalt Falls Sie mir den Inhalt des Artikels zur Verfügung stellen, kann ich Ihnen sehr gerne eine verständliche Zusammenfassung im gewünschten Stil schreiben – locker, aber korrekt, und verständlich für Zehntklässler. Das wäre perfekt für ein Newsportal für Menschen mit Psoriasis oder Psoriasis arthritis. Originaltitel: JLE - European Journal of Dermatology - Mortality, prevalence, comorbidity, and flare patterns in generalised pustular psoriasis: a comprehensive literature review Link zur Quelle

# Neue Technologie zur Psoriasis-Diagnose Forscher haben eine neue Methode entwickelt, um Psoriasis früher und genauer zu erkennen[1]. Sie heißt Multiphoton-Mikroskopie und schaut sich die Haut von innen an, ohne dass man sie verletzten muss. Das Besondere daran ist, dass die Methode sehr genau arbeitet[1]. Sie zeigt nicht nur die oberflächliche Hautveränderung, sondern auch die winzigen Blutgefäße und tieferen Hautschichten. Bei Psoriasis-Patienten sind diese Gefäße deutlich dicker als bei gesunden Menschen – etwa doppelt so groß[1]. Das hilft nicht nur bei der Diagnose. Die Technologie kann auch kontrollieren, ob eine Behandlung funktioniert[2]. Man sieht direkt, ob die Blutgefäße wieder kleiner werden und die Entzündung nachlässt. Bisher musste man dafür eine Hautprobe nehmen – das ist schmerzhaft und hinterlässt eine Narbe[1]. Experten sehen darin großes Potenzial. Mit dieser Methode können Ärzte ihre Therapie besser abstimmen und Patienten schneller sehen, ob die Behandlung anschlägt[2]. Originaltitel: In vivo multiphoton microscopy of psoriasis: A new diagnosis and therapeutic monitoring technique Link zur Quelle

Psoriasis is a chronic inflammatory skin disease, and noninvasive diagnostic tools are essential for accurate diagnosis and treatment monitoring. Multiphoton microscopy (MPM) enables real-time, noninvasive skin imaging with submicron resolution. This study evaluated the diagnostic accuracy of MPM in psoriasis and its potential application in therapeutic monitoring. This prospective observational study enrolled 34 patients with psoriasis. It comprised three parts: (1) analysis of imaging features of lesional and nonlesional skin using multiphoton microscopy (MPM; Transcend Vivoscope); (2) evaluation of the diagnostic performance of MPM parameters compared with reflectance confocal microscopy (RCM); and (3) prospective monitoring of 24 patients treated with Benvitimod (Tapinarof) cream for 8 weeks (T0/T1/T2). MPM detected psoriasis characteristics (including hyperkeratosis, parakeratosis, an absent stratum granulosum, enlarged nucleus diameter, and absent bright rimming) with comparable diagnostic efficiency to RCM (AUC = 0.838, p < 0.001 vs. 0.824, p < 0.001). Psoriatic lesions showed significant perinuclear fluorescence accumulation compared to healthy skin (p < 0.001). All imaging features improved significantly after 8 weeks of treatment (p < 0.001). PASI/TLS scores showed correlations with the epidermal thickness (r = 0.403/0.492, p < 0.001), nuclear diameter (r = 0.4/0.375, p < 0.001), and fluorescence intensity (r = -0.419/-0.492, p < 0.001). MPM is a novel and non-invasive imaging technique for psoriasis evaluation and treatment monitoring.Weiterlesen

No abstract supplied.Weiterlesen

This first part of the updated German S3 guideline on the treatment of psoriasis vulgaris covers the sections on treatment recommendations, treatment goals, and monitoring of therapies. The recommendations are based on the current Cochrane network meta-analysis, the results of which are also summarized. When selecting systemic therapies for psoriasis vulgaris, the guideline emphasizes consideration of efficacy, safety, comorbidities, and individual patient factors. The decision framework is presented in the treatment options overview, and in this updated version, the possibility of first-line therapy with biologics or novel targeted small molecules is more prominently highlighted. Standardized instruments for assessing disease severity, as well as patient-centered treatment goals, are underscored. A Psoriasis Area and Severity Index (PASI) 75 response is defined as the minimum therapeutic target, while PASI 90 or an absolute PASI <2 are considered desirable goals. Since the last version, two newly approved agents, bimekizumab and deucravacitinib, have been incorporated, accompanied by specific usage recommendations. Among the established therapies, guidance on methotrexate has been extensively revised, particularly regarding administration, dosing, and monitoring. This guideline aims to provide clinicians with an evidence-based framework for therapy selection and monitoring, while strengthening shared decision-making with patients.Weiterlesen

Background and objectivesPeople with skin disease often experience stigmatization in health and body care settings, significantly impacting their quality of life. This parallel-group randomized controlled trial evaluated a face-to-face group seminar aimed at reducing stigma towards people with skin disease among health and body care professionals (HBCPs).Patients and methodsCosmetologists, hairdressers, nurses, and physical therapists were randomized into an intervention (IG; n = 64) or control group (CG; n = 65). The IG received a seminar consisting of self-awareness exercises, education and a patient encounter; the CG followed a seminar on "health at work". Stereotype agreement, disease-related misconceptions, desire for social distance, and behavioral intentions were assessed at baseline (t0), post-intervention (t1), and 3 months follow-up (t2).ResultsThe intervention group showed significant reductions over time in disease-related misconceptions (t0-t1: 0.398, p < 0.001; t0-t2: 0.225, p < 0.001; ηp2 = 0.12) and in stereotype endorsement (t0-t1: 0.392, p < 0.001; t0-t2: 0.299, p = 0.002; ηp2 = 0.12). In both groups, the desire for social distance decreased immediately after the seminar (t0-t1Intervention: 0.186, p < 0.001; t0-t1Control: 0.135, p = 0.012) but returned to baseline at follow-up (t0-t2Intervention: 0.097, p = 0.35; t0-t2Control: 0.016, p = 1.00).ConclusionsThe seminar improved skin disease-related stigmatizing beliefs and attitudes of HBCPs. Its integration into vocational training curricula or delivery in workshops to increase knowledge about skin diseases and to reduce prejudices in various professional groups is promising.Weiterlesen

Background and objectivesPalmoplantar pustulosis (PPP) is a chronic and refractory inflammatory skin disorder with unclear pathogenesis.Patients and methodsTen PPP patients treated with upadacitinib were monitored to assess efficacy and safety. Immunofluorescence and immunohistochemistry were employed to evaluate Th1, Th2, and Th17 cell expressions, along with their associated cytokines in lesions on palms or soles from 16 PPP patients, 10 chronic eczema (CE) patients, 10 psoriasis vulgaris (PV) patients, and 7 healthy controls (HC).ResultsIn PPP patients receiving upadacitinib, the shortest time to achieve PPPASI75 and PPPASI90 was 4 weeks and 8 weeks, respectively. The rates of patients achieving PPPASI90 at week 16, week 24, and week 52 was 70 %, 100 %, and100 %, respectively. Th1 cells and IFN-γ levels in PPP were comparable to CE and PV, and higher than HC. Th2 cells, IL-4, and IL-13 levels in PPP were similar to CE, and greater than HC and PV. Th17 cells, IL-17, and IL-36γ levels in PPP were comparable to PV, and more abundant than HC and CE.ConclusionsUpadacitinib is a safe and effective option for PPP patients, which may be attributed to the complex Th1, Th2, and Th17 inflammatory responses associated with PPP.Weiterlesen

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

Acne tarda is defined in the literature as adult acne, which according to most authors occurs in women aged 25 and older. However, the definitions and age groups vary depending on the study. Current guidelines rarely address adult acne. In this review, current studies and the literature on acne tarda are analyzed and evaluated by German experts. Recommendations regarding classification, clinical features, differentiation, and treatment of acne tarda were summarized in a consensus based on the discussion. The recommendations also include the treatment of post-inflammatory erythema/hyperpigmentation and acne scars, as well as the accompanying skin care. The goal is to improve the treatment of patients with acne tarda.Weiterlesen

BackgroundPsoriasis is a chronic autoimmune skin condition that significantly impacts an individual's quality of life, resulting in physical discomfort, psychological distress, and compromised social well-being. However, there is limited understanding regarding the challenges faced by patients in Malaysia. This study examines the lived experiences of patients with psoriasis in Malaysia, focusing on the emotional, social, financial, and treatment-related challenges they face, as well as the coping mechanisms they employ.MethodsA qualitative, phenomenological approach was employed among members of the Psoriasis Association Malaysia. Purposive sampling was used to recruit adult participants who were capable of participating in the online interview. Data collection involved the use of Google Forms, which included the Malay version of the Dermatology Life Quality Index questionnaire, supplementing the qualitative findings. This was followed by semi-structured online interviews conducted via video conferencing. Thematic analysis was conducted using NVivo version 14, and descriptive analysis was performed using SPSS version 28.ResultThis study involved 30 respondents with a mean age of 44 years diagnosed with psoriasis. The mean (SD) for the duration of illness is 21.3 (11.8) years. About 70% respondents reported that psoriasis had a moderate to very high impact on their quality of life. Thematic analysis has identified six major themes, including physical devastation, emotional burden, disruption in social functioning, treatment hurdles and advancements, financial barriers, and behavioral adaptation.ConclusionPsoriasis imposes complex challenges that extend beyond physical symptoms, affecting emotional well-being, social interactions, financial stability, and treatment struggles. In response to the various challenges that arose, respondents developed behavioral adaptations to achieve a better quality of life. Framed within the biopsychosocial model, the findings emphasize the need for a holistic, patient-centred approach to psoriasis care that integrates medical treatment with psychological support and social interventions to improve overall quality of life.Weiterlesen

BackgroundPsoriasis affects approximately 2% of the global population, with the IL-17A-STAT3 pathway mediating abnormal keratinocyte proliferation and inflammatory amplification. Solanum lyratum (Bai Ying) has long been used for skin disorders, and its steroidal alkaloids have anti-inflammatory potential, though the mechanisms remain unclear.ObjectiveTo elucidate the molecular basis and cytological efficacy of S. lyratum steroidal alkaloids in exerting anti-psoriatic effects via the IL-17A/STAT3 axis.MethodsHPLC-MS-QTOF, network pharmacology, molecular simulation, and a HaCaT cell model with STAT3-siRNA assays were employed.ResultsEighteen components were identified; steroidal alkaloids showed high affinity for STAT3 and IL17RA. S. lyratum (5-40 μg/mL) enhanced cell viability, inhibited p-STAT3 (IC50 = 14.30 μg/mL), and attenuated inflammatory responses and keratinocyte proliferation.ConclusionS. lyratum steroidal alkaloids exert dual-targeted blocking effects on the IL-17A/STAT3 axis, supporting it as a potential therapeutic candidate for psoriasis.Weiterlesen

IntroductionTreatment of moderate to severe psoriasis typically requires the use of multiple systemic therapies over a patient's lifetime. The efficacy and safety of systemic treatments are typically evaluated in clinical trials; however, patient registries are increasingly used to monitor long-term outcomes of systemic therapies for psoriasis in real-world settings. Psoriasis registries also generate important real-world evidence about psoriasis treatment that may facilitate a greater understanding of outcomes outside of a controlled clinical trial setting. This study thus characterises the design and measures used in real-world studies of psoriasis treatment from patient registries and assesses its use in informing clinical guidelines and reimbursement decisions.Methods and analysisA systematic literature review was conducted to identify real-world observational studies that used psoriasis registry data. PubMed and Embase were searched for English-language studies published between January 2018 and January 2023. To assess how real-world studies, clinical guidelines, and reimbursement and coverage reports have informed practice, treatment, and reimbursement guidelines, a narrative review of recommendations was conducted. All results were screened by two independent reviewers (LP and TAS) using prespecified inclusion and exclusion criteria. Outcomes of interest were extracted into Excel, with all conflicts resolved through discussion/consensus. Tables displayed outcomes and research topics first by year, then by registry.Prospero registration numberCRD42023402431.Weiterlesen

ObjectivesTo assess the incidence and risk factors for arrhythmias in patients with psoriatic arthritis (PsA).MethodsWe performed a cohort analysis of patients followed prospectively from 1994 to 2024. Participants were evaluated using standard protocols at 6-to-12-month intervals. The following events were assessed: (1) atrial tachyarrhythmia (including atrial fibrillation and supraventricular tachycardia); (2) ventricular tachyarrhythmia and (3) bradycardia/pacemaker. The cumulative incidence rate (CIR) of each arrhythmia was calculated. Cox proportional hazards models (reported as the current level HR (measured just prior to the event) and the adjusted mean HR) were fitted to assess the association between selected measures of PsA disease activity and the age of occurrence of arrhythmia events. Each model was adjusted for sex, PsA duration, cardiovascular risk factors and medications.ResultsA total of 1670 patients with PsA were analysed (80 atrial tachyarrhythmias, 17 bradyarrhythmias/pacemakers and 11 ventricular tachyarrhythmias). By age 70, the CIRs were 7.82%, 0.67% and 0.45% for atrial, ventricular and bradycardia, respectively. In multivariable analysis, remission/low versus high disease activity state was associated with lower risk of atrial tachyarrhythmia (current HR 0.49, 95% CI 0.26 to 0.92; adjusted mean HR 0.46, 95% CI 0.23 to 0.91). Similarly, a higher three-item Visual Analogue Scale (3-VAS) was associated with a higher risk of atrial tachyarrhythmia (current level HR 1.18, 95% CI 1.04 to 1.33; adjusted mean HR 1.22, 95% CI 1.04 to 1.44).ConclusionsHigher PsA disease activity is associated with higher atrial tachyarrhythmia risk. These findings reinforce the importance of controlling inflammation in PsA to optimise cardiac health.Weiterlesen

Abstract Atopic dermatitis and psoriasis are two dermatological diseases that affect the mental health of patients. The purpose of this research is to investigate the comparison of the psychometric characteristics of two groups of patients with psoriasis and atopic dermatitis respectively focusing on depression, personality, hostility and psychosomatic burden. Τhe sample was consisted by 100 patients with psoriasis and 40 patients with atopic dermatitis, respectively. Specific questionnaires were given for the psychometric evaluation of patients with atopic dermatitis and psoriasis. The Beck's Depression Inventory (BDI), the Eysenck Personality Questionnaire (EPQ) the Brief Symptom Inventory SCL-90 scale, and the HDHQ questionnaire (Psychometric Hostility and Direction of Hostility Questionnaire). Patients with atopic dermatitis have statistically significantly higher scores on the scale of somatization and paranoid ideation, while patients with psoriasis have statistically significantly higher scores on the scale of depression. On the personality scales, patients with atopic dermatitis have on average statistically significantly higher scores on the psychoticism scale and lower scores on the lying scale than the psoriatic patients. Patients with atopic dermatitis present statistically significantly higher scores on the scale of paranoid hostility than patients with psoriasis. Patients receiving medication as well as the interaction of disease group with receiving medication are statistically significantly related to the psychopathology index. Patients' scores on the psychotic scale of the EPQ are statistically significantly related to the duration of the illness and the patient group, gender and medication intake. The psychosocial effects of psoriasis and atopic dermatitis on patients' mental health are demonstrated in the present study based on patient scores on psychometric scales and psychopathology index. Weiterlesen

No abstract supplied.Weiterlesen

Dual biologic therapy is not often used in psoriasis and psoriatic arthritis due to cost and safety concerns, with limited literature supporting its use. We present a case of a 31-year-old man with severe plaque psoriasis and erosive psoriatic arthritis, refractory to multiple therapies. While guselkumab improved skin symptoms, joint inflammation persisted. Given the patient's reluctance to discontinue guselkumab and his poor response to prior therapies, bimekizumab was added. This combination led to near-complete skin clearance and significant joint improvement within 3 months, with sustained benefits and no adverse effects at 17 months. This case illustrates how targeting multiple points in the interleukin-23/interleukin-17 pathway can improve outcomes in patients unresponsive to monotherapy. Dual biologic therapy may be a viable option for select patients with complex disease, though further research is needed to evaluate its long-term safety and efficacy.Weiterlesen

IntroductionPsoriasis is a chronic inflammatory disease associated with multiple systemic comorbidities and reduced quality of life. Risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in achieving rapid and sustained skin clearance in moderate-to-severe psoriasis. However, its impact on chronic subclinical inflammation is less understood. Conventional clinical assessments like Psoriasis Area and Severity Index (PASI), Investigator's Global Assessment (IGA), and Body Surface Area (BSA) focus on evaluating visible symptoms and are limited in capturing underlying disease activity. Optical coherence tomography (OCT), a non-invasive imaging modality, offers real-time assessment of structural and vascular changes, providing valuable insights beyond the skin surface.MethodsThis sub-analysis of a prospective, single-center exploratory study included 22 patients with moderate-to-severe psoriasis treated with risankizumab. Clinical assessments (PASI, IGA, BSA) were conducted at baseline and weeks 2, 4, 16, 28, 40, and 52. OCT imaging performed at baseline and weeks 4, 16, and 52 evaluated epidermal thickness and vascular parameters (e.g., vessel density and diameter) in lesional and perilesional skin.ResultsBy week 16, mean (95% confidence interval [CI]) PASI score decreased from 16.3 (11.6-21.1) at baseline to 3.5 (1.8-5.2), and BSA involvement from 24.7% (16.1-33.3) to 5.2% (1.9-8.4) (both p < 0.001). By week 52, 86.7%, 73.3%, and 40.0% of patients achieved PASI 75, 90, and 100, respectively, and 93.3% achieved IGA 0/1. OCT showed lesional reductions in epidermal thickness (- 37.4%), vessel density (- 26.6% Δ area under the curve [AUC]), and vessel diameter (- 59.5% ΔAUC) over the 52-week period. Notably, vascular changes also occurred in uninvolved perilesional skin.ConclusionRisankizumab improved both clinical and OCT parameters over 52 weeks, emphasizing the importance of long-term therapy with benefits extending beyond visible improvement. OCT emerged as a valuable tool for assessing deep (vascular) treatment response, thereby supporting a more comprehensive understanding of therapeutic outcomes in psoriasis.Weiterlesen

IntroductionThe German national psoriasis registry PsoBest collects long-term data on the effectiveness, safety, and tolerability of systemic treatments for psoriatic disease. Here, we describe patient characteristics and the safety and effectiveness of apremilast for the treatment of psoriatic disease in Germany based on data from PsoBest.MethodsThis was a descriptive analysis of observational data collected from PsoBest using cross-sectional (baseline characteristics) and longitudinal (outcomes, safety) designs. PsoBest recruits patients with moderate to severe plaque psoriasis or psoriatic arthritis who initiate a new systemic psoriasis treatment. Adverse events (AEs) and sociodemographic descriptors were reported for patients exposed to apremilast during the study period (safety cohort). Clinical and patient-reported outcomes were collected 3, 6, and 12 months after the initiation of apremilast monotherapy (outcomes cohort).ResultsFrom January 15, 2015 to June 30, 2020, 595 registry patients were exposed to apremilast; 417 were treated with apremilast monotherapy. Patients taking apremilast had a higher mean age and higher proportions of comorbidities such as cardiovascular or metabolic disease compared with those taking other nonbiologic systemic or biologic drugs. The most common nonserious AEs were drug ineffectiveness (14.1%), diarrhea (9.4%), nausea (7.1%), and headache (6.1%). The highest incidence rates of nonserious and serious AEs of special interest were for infections and infestations per system organ class (8.03/100 patient-years) and malignant or unspecified tumors (2.50/100 patient-years), respectively. Improvements in Dermatology Life Quality Index, patient-defined treatment benefits (Patient Benefit Index), body surface area, and Psoriasis Area and Severity Index were observed after 3, 6, and 12 months of apremilast treatment.ConclusionsPatients in routine care treated with apremilast in the German PsoBest registry experienced treatment benefits and improved skin, psoriasis severity, and quality of life. Safety was consistent with the established safety profile. Apremilast is safe and effective for treating moderate to severe psoriatic disease.Weiterlesen

BackgroundPsoriasis is a systemic inflammatory disease associated with cardiopulmonary comorbidities. Nail psoriasis, quantified by the Nail Psoriasis Severity Index (NAPSI), is a marker of severe disease. While pulmonary arterial hypertension (PAH) is reported more frequently in psoriasis, the specific correlation between nail psoriasis severity and PAH remains underexplored.ObjectiveTo investigate the correlation between NAPSI scores and the presence or severity of PAH in patients with psoriasis.MethodsA prospective, cross-sectional study was conducted at a tertiary care centre involving 100 patients with chronic plaque psoriasis (50 with and 50 without nail psoriasis). All participants underwent dermatological evaluation [Psoriasis Area and Severity Index (PASI) and NAPSI scoring], transthoracic echocardiography to estimate pulmonary artery systolic pressure (PASP), and measurement of inflammatory markers [C-reactive protein (CRP), IL-17, TNF-α]. PAH was defined as PASP > 35 mmHg. Statistical analyses included correlation tests, comparative analyses, and multivariate logistic regression.ResultsPAH was identified in 29% (n = 29) of patients, with a significantly higher prevalence in the nail psoriasis group (40% vs 18%, P = .01). Patients with PAH had higher mean NAPSI scores than those without (29.5 ± 13.4 vs 18.2 ± 10.6, P = .001). A moderate positive correlation was found between NAPSI scores and PASP (r = 0.44, P < .001). PASI scores and CRP levels were also significantly elevated in patients with PAH and correlated with PASP (r = 0.38, P = .001 and r = 0.41, P < .001, respectively).Multivariate analysis confirmed NAPSI score as an independent predictor of PAH [odds ratio (OR): 1.07/unit increase, 95% CI: 1.03-1.11, P = .002], after adjusting for confounders including PASI score and comorbidities. PASI (OR: 1.05, P = .01) and CRP (OR: 1.13, P = .008) were also independent predictors. Nail matrix involvement was more strongly associated with PAH than nail bed involvement (P = .03). Inflammatory markers (CRP, IL-17, TNF-α) were significantly elevated in patients with PAH.ConclusionNAPSI scores, PASI scores, and CRP levels are all significantly correlated with and independently predict PAH in patients with psoriasis. Assessment of nail psoriasis severity may serve as a valuable, noninvasive clinical tool to identify psoriasis patients at increased risk of pulmonary vascular complications, warranting further cardiological evaluation.Weiterlesen

Originaltitel: In vivo multiphoton microscopy of psoriasis: A new diagnosis and therapeutic monitoring technique. Link zur Quelle

**Guselkumab wirkt schnell gegen Psoriasis arthritis** Für Menschen mit Psoriasis arthritis, die auf bisherige Behandlungen nicht angesprochen haben, gibt es gute Nachrichten. Das Medikament Guselkumab zeigt in einer großen Studie beeindruckende Erfolge.[1][4] Die COSMOS Studie untersuchte knapp 300 Menschen, bei denen frühere Therapien nicht wirksam waren. Sie erhielten Guselkumab als Spritze oder ein Scheinmedikament. Das Ergebnis überraschte: Bereits nach acht Wochen spürten die Patienten mit Guselkumab deutliche Verbesserungen.[1] Ihre Gelenkschmerzen ließen nach, die Hautsymptome wurden weniger und sie hatten wieder mehr Energie. Besonders wichtig ist, dass diese Verbesserungen nicht verschwunden. Nach einem Jahr waren die Fortschritte sogar noch größer geworden. Die Menschen berichteten von weniger Schmerzen, besserer Haut und mehr Lebensqualität.[1] Manche konnten endlich wieder ihre alltäglichen Aufgaben bewältigen. Das Medikament wirkt anders als frühere Therapien. Es setzt bei einem speziellen Botenstoff an, der Entzündungen antreibt.[1] Ärzte bezeichnen dies als einen neuen Weg, die Krankheit zu behandeln. Für viele Patienten könnte Guselkumab also eine echte Lösung sein, wenn andere Medikamente nicht geholfen haben. Originaltitel: Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study. Link zur Quelle

# Chinesische Heilpflanzen gegen Psoriasis-Arthritis – Eine vielversprechende Entdeckung Forscher haben etwas Spannendes entdeckt. Sie analysierten alte chinesische Medizintexte und suchten nach Pflanzen gegen Psoriasis-Arthritis. Das Ergebnis überraschte die Experten. Sie fanden 32 Heilpflanzen. Zehn davon testeten sie im Labor. Die gute Nachricht: Drei Pflanzen zeigten neue Wirkungsweisen. Warum ist das wichtig? Die bisherigen Medikamente wirken zwar gut, verursachen aber oft Nebenwirkungen. Diese neuen Pflanzenstoffe könnten anders arbeiten. Sie könnten helfen und gleichzeitig verträglicher sein. Die Forscher verfolgten dabei eine clevere Strategie. Sie nutzten ein großes Archiv mit über 41.000 alten medizinischen Rezepten. Mit modernen Analysetools identifizierten sie die erfolgreichsten Pflanzen. Dann überprüften sie diese im Labor mit speziellen Methoden. Die Studie zeigt: Altes Wissen und moderne Forschung passen zusammen. Vielleicht entstehen so bald neue Therapien. Das könnte Menschen wie dir bei Psoriasis- Originaltitel: Data mining historical Chinese medical recipe collections and nuclear receptor profiling identify plant fractions that modulate glucocorticoid receptor activity. Link zur Quelle

# Neue Erkenntnisse: Wie Risankizumab die Haut wirklich verändert Forscher haben untersucht, wie das Medikament Risankizumab bei Schuppenflechte wirkt. Sie haben dazu 22 Patienten mit mittelschwerer bis schwerer Psoriasis behandelt. Das Besondere: Sie schauten nicht nur auf die sichtbare Haut. Sie nutzten auch eine spezielle Kamera namens OCT. Diese Kamera zeigt, was unter der Hautoberfläche passiert. Die Ergebnisse sind ermutigend. Nach 16 Wochen war der PASI-Wert (ein Messwert für Schuppenflechte) deutlich gesunken. Auch die betroffene Hautfläche wurde viel kleiner. Noch wichtiger: Die OCT-Bilder zeigten, dass auch tief in der Haut die Entzündung zurückging. Die Blutgefäße wurden weniger und dünner. Das bedeutet, dass Risankizumab nicht nur die oberflächlichen Symptome bekämpft. Das Medikament wirkt auch gegen die tiefere Entzündung. Diese Erkenntnis hilft Ärzten, die Behandlung besser zu verstehen und zu beurteilen. Originaltitel: Evaluating Risankizumab's Long-Term Effects in Psoriasis Using Optical Coherence Tomography. Link zur Quelle

Originaltitel: Joint association of cumulative workplace environmental exposures and shift work with long-term work-limiting health conditions: a prospective cohort study from the UK Biobank Link zur Quelle